Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

NCT05923190 · clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
60
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Fox Chase Cancer Center